Kiromic BioPharma announces FDA authorization of Deltacel IND application

Kiromic BioPharma announced that the FDA has authorized the company’s investigational new drug, or IND, application to initiate a Phase 1 clinical trial to evaluate Deltacel for patients with non-small cell lung cancer, or NSCLC.